Kronos Bio Q2 2024 EPS $(0.27), Sales $2.69M Beat $1.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio (NASDAQ:KRON) reported Q2 2024 earnings per share (EPS) of $(0.27) and sales of $2.69 million, significantly beating the analyst consensus estimate of $1.52 million. This represents a 44.21% increase in sales compared to the same period last year.
August 08, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio reported Q2 2024 EPS of $(0.27) and sales of $2.69 million, beating analyst estimates by 76.26% and showing a 44.21% YoY increase in sales.
The significant beat on sales estimates and the substantial year-over-year increase in sales are positive indicators for Kronos Bio. Despite the EPS loss, the strong revenue performance is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100